Blog

Eagle Biosciences will be at ASN Kidney Week in Washington, DC!

ASN Kidney Week is this week, Thursday, November 7 to Sunday, November 10, at the Walter E. Washington Convention Center. Stop by booth #2005 to learn more about Vanin-1, Klotho, Intact FGF23 and other assays that could help you with your kidney related research! We’ll be there to answer any questions you may have, or stop and say hi! We love seeing our customers!


Product Highlights

Vanin-1: Eagle Bio has two new Vanin-1 ELISA Kits. Vanin-1 is an early biomarker of renal tubular damage in drug-induced acute kidney injury, obstructive nephropathy, and diabetic nephropathy.

FluoBolt Klotho: This newest addition to our FluoBolt line of fluorescence immunoassays allows for highly sensitive measurement of Klotho, a critical biomarker for chronic kidney disease and failure, renal- and hepatocellular carcinomas, osteoporosis or cardiovascular diseases.

Intact FGF23: This CLEIA ELISA is a unique and highly accurate assay for the measurement of FGF23, which has been linked to impaired renal function.


Contact us for more information about these products.

What is Vanin-1?

Vanin-1 is an epithelial ectoenzyme activating the conversion of pantetheine into pantothenic acid (vitamin B5) and cysteamine and thus is involved in the regulation of oxidative stress and inflammation.

Why is Vanin-1 important?

The highest levels of Vanin-1 expression is assigned to renal tubular epithelial cells. Hence, Vanin-1 released from renal cells can be detected in the urine. Pre-clinical and clinical studies demonstrate that Vanin-1 is an early biomarker of renal tubular damage in drug-induced acute kidney injury, obstructive nephropathy, and diabetic nephropathy. In fact, Vanin-1 has as superior predictive value for acute kidney injury than established markers KIM-1, NGAL, or NAG .

Comparison of human urine Vanin-1 values in apparently healthy individuals and individuals with kidney disease:

Areas of Interest:

  • Acute kidney injury
  • Diabetic nephropathy
  • Drug-induced acute kidney injury
  • Obstructive nephropathy

Assay Highlights:

  • Optimized for human urine samples
  • Highly SPECIFIC and DEFINED characterized antibodies
  • RELIABLE rigorously validated according to FDA guidelines​
  • QUICK one-step ELISA

Eagle Biosciences offers the first fully validated human Vanin-1 assays in a simple-to-use ELISA:

Human Vanin-1 (urine) ELISA Assay Kit

Mouse/Rat Vanin-1 ELISA Kit

Contact us for more information about our Vanin-1 related assay kits.


Eagle Biosciences will be at ASN Kidney Week in Washington, DC!

Stop by booth #2005 to learn more about Vanin-1, Klotho, Intact FGF23 and other assays that could help you with your kidney related research! We’ll be there to answer any questions you may have, or stop and say hi! We love seeing our customers!

The Eagle Biosciences MedFrontier FGF23 (Human Intact FGF23) CLEIA ELISA Assay was used in a recently published study looking at the association between FGF23 levels and major adverse cardiovascular events (MACE) and mortality in patients with type 2 diabetes and normal or mildly impaired kidney function.

FGF23 is an endocrine hormone involved in vitamin D metabolism and phosphorous level regulation. Previous studies have shown a link between insulin resistance and an increase in FGF23, which researchers believe affects renal phosphorous handling and leads to a higher risk of MACE.

The study did find evidence of a connection with FGF23 levels and an increased risk of MACE or mortality in participating patients.

Read more about this study here.

Contact us for more information about this kit.

Study Citation:
Fibroblast Growth Factor 23 and Mortality in Patients With Type 2 Diabetes and Normal or Mildly Impaired Kidney Function
Stanley M.H. Yeung, S. Heleen Binnenmars, Christina M. Gant, Gerjan Navis, Ron T. Gansevoort, Stephan J.L. Bakker, Martin H. de Borst, Gozewijn D. Laverman
Diabetes Care Sep 2019, dc190528; DOI: 10.2337/dc19-0528

Eagle Biosciences proudly offers a broad range of products in our extensive catalog. In addition to the well known ELISA format, we offer several assay kits in a Chemiluminescent Enzyme Immunoassay (CLEIA) format.

ELISA vs. CLEIA

ELISAs use antibodies to detect the presence of a protein in a liquid sample. In the most common form, antigens are applied to a stable surface (usually a microtiter plate). Then the corresponding antibody, linked with an enzyme, is added to form a complex. Finally, the enzyme’s substrate is added, which produces a measurable reaction, usually in the form of a color change.

CLEIAs also utilize antibody-enzyme reactions, but offer a higher level of sensitivity due use of chemiluminescence rather than colorimetric absorbance or fluorescence. Chemiluminescence allows detection of trace amounts of analytes because samples typically have little to no background interference. These reactions are also easily measured using a photomultiplier or photodiode. These types of kits are increasing in popularity due to their increased sensitivity, specificity, reliability, and reproducibility.

Our available CLEIA/CLIA kits

Cyclic GMP CLIA Kit (High-Sensitivity)
Cyclic AMP CLIA Kit (High-Sensitivity)
Cortisone CLIA Kit
GFAP (Glial Fibrillary Acidic Protein) CLIA Assay Kit
MedFrontier FGF23 (Human Intact FGF23) CLEIA ELISA Assay

Contact us if you are looking for a specific CLEIA or if you have questions about any of our products.

Eagle Biosciences is excited to announce the addition of several new ELISA assay kits. These new assays cover a broad range of immunology research areas, including autoimmune diseases, cardiovascular diseases and cancer immunology. The majority of these kits are available in 1×96 and 2×96 well sizes.

New Kits:
Human Azurocidin ELISA Kit
Human BPI ELISA Kit
Human C3a ELISA Kit
Human C3c ELISA Kit
Human C5a ELISA Kit
Human Coagulation Factor XII ELISA Kit
Human Ficolin-1 ELISA Kit
Human Ficolin-2 ELISA Kit
Human Ficolin-3 ELISA Kit
Human gC1qR ELISA Kit
Mouse H-FABP ELISA Kit
Human L-FABP ELISA Kit
Human MAp44 ELISA Kit
Human MASP-3 ELISA Kit
Human MBL ELISA Kit
Mouse MBL-A ELISA Kit
Mouse MBL-C ELISA Kit
Competitive MGO ELISA Kit
LBP ELISA Kit
Mouse MPO ELISA Kit
Rat MPO ELISA Kit
Human Pentraxin 3 ELISA Kit
Human Proteinase 3 ELISA Kit
Human SAP ELISA Kit
Human Soluble Mannose Receptor ELISA Kit
Human sTNF-RII ELISA Kit
Human sTREM-1 ELISA Kit
Human TRACP5a ELISA Kit

Contact us for more information about our new products.

Glycoprotein 2 (GP2), the pancreatic major zymogen granule membrane glycoprotein, is has been recognized in recent years as the major antigenic target of Crohn’s Disease specific anti-pancreatic antibodies. Anti-Glycoprotein (Anti-GP2) IgA and IgG antibodies have been studied as critical biomarkers for the detection of a number of diseases, including Crohn disease, ulcerative colitis, pancreatitis, and inflammatory bowel disease.

Pancreatitis GP2 ELISA

Eagle partner Generic Assays offers a highly sensitive ELISA for the detection of acute pancreatitis-specific GP2 in serum.

Read more about related products by following these links:
Pancreatitis GP2
Sharpening the CD/UC discrimination: Antibodies to Glycoprotein 2
Pancreatic GP2-Specific Auto-Antibodies are Markers of Crohn’s Disease

GP2 Antibody Assays can be found here:

Anti-GP2 (Glycoprotein 2) IgA ELISA Assay Kit
Anti-GP2 (Glycoprotein 2) IgG ELISA Assay Kit

Contact us for more information about our GP2 related assay kits.

References

Lael Werner, Daniela Paclik, Christina Fritz, Dirk Reinhold, Dirk Roggenbuck, Andreas Sturm. Identification of Pancreatic Glycoprotein 2 as an Endogenous Immunomodulator of Innate and Adaptive Immune Responses. The Journal of Immunology. September 15, 2012, 189 (6) 2774-2783; DOI: 10.4049/jimmunol.1103190. https://doi.org/10.4049/jimmunol.1103190

Bogdanos, Dimitrios P.; Roggenbuck, Dirk; Reinhold, Dirk; Wex, Thomas; Pavlidis, Polychronis; von Arnim, Ulrike; Malfertheiner, Peter; Forbes, Alastair; Conrad, Karsten; Laass, Martin W. (2012) Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn’s disease. BMC Gastroenterology. 102 (12) 1; DOI: 10.1186/1471-230X-12-102. https://doi.org/10.1186/1471-230X-12-102

Roggenbuck, D., Goihl, A., Hanack, K., et al. (2016). Serological diagnosis and prognosis of severe acute pancreatitis by analysis of serum glycoprotein 2. Clinical Chemistry and Laboratory Medicine (CCLM), 55(6), pp. 854-864. Retrieved 23 Sep. 2019, from doi:10.1515/cclm-2016-0797.

Valentina Somma, Hani Ababneh, Ahmad Ababneh, et al., “The Novel Crohn’s Disease Marker Anti-GP2 Antibody Is Associated with Ileocolonic Location of Disease,” Gastroenterology Research and Practice, vol. 2013, Article ID 683824, 7 pages, 2013. https://doi.org/10.1155/2013/683824.

Shulan Zhang, Ziyan Wu, Jing Luo, Xuefeng Ding, Chaojun Hu, Ping Li, Chuiwen Deng, Fengchun Zhang, Jiaming Qian, Yongzhe Li. (2015). Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients with Crohn Disease. Medicine, 94 (42). doi: 10.1097/MD.0000000000001654.

Our Anti-Phospholipid IgM and IgG Line Immunoassays were used in two recent studies. These assays are part of our DotDiver line of products from Generic Assays (designed for use with the DotDiver 2.0 Immunoassay Processor).

The first study performed a comparison of the line immunoassays versus the ELISA method to evaluate the sensitivity and specificity. The second study focused on using line immunoassays to examine thrombotic risk of non-criteria anti-phospholipid antibodies. Abstracts and citation information for both studies are below.

Product pages:
DotDiver Anti-Phospholipid IgM
DotDiver Anti-Phospholipid IgG

Contact us for more information about out DotDiver products.


Evaluation of the sensitivity and specificity of a novel line immunoassay for the detection of criteria and non-criteria antiphospholipid antibodies in comparison to established ELISAs. (Full Article)

Abstract Background:
Persistent antiphospholipid antibodies (aPL) constitute the serological hallmark of the anti-phospholipid syndrome (APS). Recently, various new assay technologies for the detection of aPL better suited to multiplex reaction environments than ELISAs emerged. We evaluated the diagnostic performance of such a novel line immunoassay (LIA) for the simultaneous detection of 10 different aPL.

Thaler MA, Bietenbeck A, Steigerwald U, Buttner T, Schierack P, Lindhoff-Last E, et al. (2019) Evaluation of the sensitivity and specificity of a novel line immunoassay for the detection of criteria and non-criteria antiphospholipid antibodies in comparison to established ELISAs. PLoS ONE 14(7): e0220033. https://doi.org/10.1371/journal.pone.0220033


Thrombotic Risk of Non-Criteria Anti-Phospholipid Antibodies Measured by Line Immunoassay: Superiority of Anti-Phosphatidylserine and Anti-Phosphatidic Acid Antibodies  (Full Article)

Abstract Background:
Increasing interest has focused on the development of new assays more specific for APS and application of multiple combinations of anti-phospholipid antibodies (aPLs). This study explored the thrombotic risk of non-criteria aPLs measured by a new line immunoassay (LIA) and the benefit of additional non-criteria aPLs results to the APS diagnosis.

Park HS, Gu JY, Jung HS, Kim HK. (2019) Thrombotic risk of non-criteria anti-phospholipid antibodies measured by line immunoassay: superiority of anti-phosphatidylserine and anti-phosphatidic acid antibodies. Clin. Lab. 2019;65:207-213. DOI: 10.7754/Clin.Lab.2018.171207

Eagle Biosciences is excited to announce some new product offerings from Svar Life Science. These new products include a C4d ELISA Kit and a Total Complement ELISA Kit.

About Svar

Svar is a Swedish Life Science company that has been providing diagnostic laboratory services for nearly 30 years. Founded as Euro Diagnostic in 1992, the company rebranded in 2018 to Svar, which means “answers” in Swedish. They specialize in autoimmunity, inflammatory diseases and oncology. In addition to providing dedicated laboratory services, they produce cell based assays and immunoassays.

→ Complement C4d ELISA Assay Kit

The Complement C4d ELISA Assay Kit is intended for the semi-quantitative determination of C4d in human plasma. The complement system is an essential part of the immune system that assists antibodies and phagocytes in clearing cellular debris, promoting inflammation and attacking pathogen cell membranes. The C4d protein is a product of the classical and lectin pathways of the complement system. C4d as a biomarker is associated with antibody-mediated rejection, as well as with diagnosing and monitoring Systematic Lupus Erythematous (SLE) and other autoimmmune diseases.

→ Total Complement Functional Screen ELISA

The Total Complement Functional Screen ELISA used for the qualitative determination of functional classical, MBL, and alternative complement pathways in human serum. This kit combines principles of the hemolytic assay for complement activation with the use of labeled antibodies specific for neoantigen produced as a result of complement activation. The amount of neoantigen generated is proportional to the functional activity of complement pathways.

Contact us for more information about these or any of our other Svar products

 

 

 

 

Eagle Biosciences will be at the American Society for Bone and Mineral Research annual meeting this weekend, September 20-23 in Orlando. ASBMR 2019 is taking place at the Orange County Convention Center.

We have booth #626 stop by and see us!

We are especially excited to highlight our Intact FGF23 CLEIA and Fluobolt kits from our line of Bone Metabolism assays.

 

About ASBMR

The ASBMR Annual Meeting is the world’s largest and most diverse meeting in the bone, mineral and musculoskeletal research field, attracting more than 3,000 attendees from more than 70 countries, including clinicians and researchers, representing all career levels and specializing in a variety of disciplines.

Contact us to set up a meeting or for more information about our bone metabolism kits

Eagle Biosciences partner Fianostics completed a study evaluating their Noggin and Asporin FluoBolt assays as biomarkers for non-alcoholic fatty liver disease (NAFLD). The study shows that NOGGIN and ASPORIN may be valuable biomarkers for the diagnosis of NAFLD patients and they may also mediate the favorable effect of vitamin E treatment, although mechanistic studies are needed. Further studies with higher patient numbers are also required to confirm these promising results. The study helps support that these highly sensitivity assays allow researchers to measure a decrease of both markers in samples from NAFLD patients. This measurement is not possible with less sensitive methods. This indicates that noggin and asporin may be valuable biomarkers for NAFLD diagnosis.

Read More

FluoBolt Kits:
Noggin
Asporin

Contact us for more information about these kits or our other FluoBolt offering.